Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on BioLife Solutions, with a price target of $33.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Flaten covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Evaxion Biotech, and Personalis. According to TipRanks, Flaten has an average return of 11.2% and a 51.89% success rate on recommended stocks.

In addition to Lake Street, BioLife Solutions also received a Buy from TD Cowen’s Brendan Smith in a report issued today. However, on the same day, TipRanks – Google reiterated a Hold rating on BioLife Solutions (NASDAQ: BLFS).

Based on BioLife Solutions’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $18.79 million and a net profit of $3.54 million. In comparison, last year the company had a net profit of $12.46 million

Based on the recent corporate insider activity of 125 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Most recently, in December 2025, Sarah Aebersold, the CHRO of BLFS sold 713.00 shares for a total of $17,439.98.